Clinical Trials Sponsored by Methodos Laboratory

Total 1341 results

Changping Laboratory

Recruiting

pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression

Major Depressive Disorder | Treatment Resistant Depression

China
Changping Laboratory

Not yet recruiting

pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression

Major Depressive Disorder | Treatment Resistant Depression | MDD
Changping Laboratory

Recruiting

rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS

Major Depressive Disorder | Treatment Resistant Depression | MDD

China
Changping Laboratory

Recruiting

pBFS-guided Dual-target cTBS for Aphasia After Stroke

Stroke | Aphasia

China
Universidade do Vale do Sapucai
Pfizer; Apsen Farmaceutica S.A.; Biofarma; Dermadia; Methodos Laboratory

Completed

Prevention of Complications (SARS-CoV-2): Clinical Study

Complication

Brazil
Changping Laboratory

Recruiting

pBFS-guided cTBS at Different Doses for Aphasia After Stroke

Stroke | Aphasia

China
Changping Laboratory

Not yet recruiting

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder | OCD
Changping Laboratory

Recruiting

pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder

Depression | Major Depressive Disorder | Severe Depression

China
Changping Laboratory

Not yet recruiting

pBFS Guided 20min Inter-session Interval rTMS Treatment for MDD

Major Depressive Disorder | Severe Depression | Moderate Depression
Changping Laboratory

Recruiting

pBFS-guided Multi-target cTBS for Aphasia After Stroke

Stroke | Aphasia

China
Changping Laboratory

Not yet recruiting

pBFS-guided iTBS Over the Superior Temporal Gyrus for Aphasia After Ischemic Stroke

Aphasia | Stroke, Ischemic
Changping Laboratory

Not yet recruiting

pBFS-guided cTBS Combined With iTBS Over the Superior Frontal Gyrus for Aphasia After Ischemic Stroke

Aphasia | Stroke, Ischemic
Changping Laboratory

Not yet recruiting

pBFS-guided cTBS Over the Superior Temporal Gyrus for Aphasia After Ischemic Stroke

Aphasia | Stroke, Ischemic
Changping Laboratory

Recruiting

pBFS-Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression

Major Depressive Disorder | Treatment Resistant Depression | MDD

China
Changping Laboratory

Recruiting

pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression

Major Depressive Disorder | Treatment Resistant Depression | MDD

China
Changping Laboratory

Recruiting

pBFS Guided rTMS Therapy for Treatment-resistant Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder | OCD

China
Changping Laboratory

Recruiting

pBFS Guided VS "5-cm Rule" rTMS Over DLPFC for MDD

Major Depression | MDD

China
Changping Laboratory

Recruiting

Individualized Precision rTMS for Language Recovery in Patients After Ischemic Stroke: a Multi-center RCT

Aphasia | Stroke, Ischemic

China
Tongue Laboratory

Unknown

Efficacy Study of the Medical Device TRP Snorless™ in the Treatment of Snoring (SCORED)

Snoring

Czechia
Milkhaus Laboratory

Unknown

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

Prostatic Hyperplasia

United States
Bio Products Laboratory

Completed

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

Factor 10 Deficiency

United States
Bio Products Laboratory

Terminated

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

Haemophilia A

Colombia, Germany, Poland
Bio Products Laboratory

Terminated

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery (Ten03)

Factor X Deficiency

United Kingdom, United States, Spain, Turkey
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
Bio Products Laboratory

Completed

A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency

Primary or Secondary Antibody Deficiency

United Kingdom
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
Bio Products Laboratory

Completed

A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

Primary Antibody Deficiency

United Kingdom
Bio Products Laboratory

Completed

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases (GMX07)

Common Variable Immunodeficiency | Primary Immune Deficiency Disorders | Hyper-IgM Syndrome | X-linked Agammaglobulinaemia

United States, United Kingdom, Hungary
Bio Products Laboratory

Completed

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

Common Variable Immunodeficiency | Wiskott-Aldrich Syndrome | X-linked Agammaglobulinemia | Primary Immune Deficiency Disorders | Hyper-IgM Syndrome

United States, Chile, Israel
Bio Products Laboratory

Completed

A Study Investigating Treatment Factor X in People With Factor X Deficiency

Factor X Deficiency

United States, Turkey, Germany, Spain, United Kingdom
Bio Products Laboratory

Completed

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura

United States, India, Argentina
Munich Leukemia Laboratory

Recruiting

Better Leukemia Diagnostics Through AI (BELUGA) (BELUGA)

Lymphoma | Leukemia | Hematologic Malignancy | Minimal Residual Disease | Blood Cancer

Germany
Bio Products Laboratory

Completed

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

Healthy

United States
Bio Products Laboratory

Completed

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (SCIG03)

Common Variable Immunodeficiency | Primary Immune Deficiency Disorders | X-linked Agammaglobulinaemia | Hyperimmunoglobulin M Syndrome

United States
Bio Products Laboratory

Completed

A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years

Factor X Deficiency

United Kingdom
Bio Products Laboratory

Completed

A Study Comparing the Pharmacokinetics and Tolerance of D-Gam® to Rhophylac® in Rh-D-negative Healthy Volunteers.

Healthy

United Kingdom
Bio Products Laboratory

Completed

A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg in Healthy Volunteers

Healthy

United Kingdom
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Bio Products Laboratory

Completed

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

Primary Immunodeficiency | Wiskott-Aldrich Syndrome | Hypogammaglobulinemia | Common Variable Hypogammaglobulinemia | X-linked Hypogammaglobulinemia | Immunodeficiency With Hyper-IgM

United States
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

vonWillebrand's Disease

Israel
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

Haemophilia B

Poland, Ukraine
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B

Haemophilia B

United Kingdom
Lescuyer Laboratory
BioFortis

Completed

Dose Effect of Limicol on (LDL)-Cholesterol Levels

Hypercholesterolaemia

France
Lescuyer Laboratory
BioFortis

Completed

Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia

Delivery of Health Care

France
Bio Products Laboratory

Terminated

Optivate in People With Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

Israel, United Kingdom
Bio Products Laboratory

Terminated

A Study With OPTIVATE® in People With Von Willebrand Disease

Von Willebrand Disease

Israel, United Kingdom

Clinical Trials Sponsored by Methodos Laboratory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations